Commonwealth Equity Services LLC Sells 29,350 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Commonwealth Equity Services LLC decreased its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 63.9% in the 4th quarter, HoldingsChannel reports. The firm owned 16,600 shares of the biopharmaceutical company’s stock after selling 29,350 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Dynavax Technologies were worth $212,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Saturna Capital Corp bought a new position in shares of Dynavax Technologies in the fourth quarter valued at about $174,000. Wealthfront Advisers LLC acquired a new stake in Dynavax Technologies in the 4th quarter valued at about $193,000. AlphaQuest LLC raised its stake in shares of Dynavax Technologies by 10.2% in the fourth quarter. AlphaQuest LLC now owns 23,437 shares of the biopharmaceutical company’s stock worth $299,000 after acquiring an additional 2,172 shares during the last quarter. Amundi lifted its position in shares of Dynavax Technologies by 172.6% during the fourth quarter. Amundi now owns 58,896 shares of the biopharmaceutical company’s stock worth $743,000 after purchasing an additional 37,290 shares in the last quarter. Finally, E Fund Management Co. Ltd. grew its stake in shares of Dynavax Technologies by 4.6% during the fourth quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 771 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DVAX. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Trading Up 2.4 %

Shares of NASDAQ DVAX opened at $12.03 on Thursday. The company’s 50 day simple moving average is $13.28 and its 200 day simple moving average is $12.57. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The firm has a market capitalization of $1.49 billion, a P/E ratio of 66.83 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. The business had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, analysts predict that Dynavax Technologies Co. will post 0.32 EPS for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.